Microphage Inc. Seeks FDA Clearance to Market World’s First Test Designed to Rapidly Identify Bacterial Infections and Antibiotic Susceptibility

LONGMONT, Colo.--(BUSINESS WIRE)-- MicroPhage announced that it has submitted human data from a pivotal clinical study of its ‘Microphage MRSA/MSSA Blood Culture Test’ to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented Bacteriophage Amplification platform technology. MicroPhage further announced that it has already begun OUS commercial shipments of the test.